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Germline Susceptibility to Colorectal Cancer Due to Base-Excision Repair
Gene Defects
Susan M. Farrington,1,4,* Albert Tenesa,1,4,* Rebecca Barnetson,1,4 Alice Wiltshire,1,4
James Prendergast,1,4 Mary Porteous,1,2 Harry Campbell,1,3 and Malcolm G. Dunlop1,2
1Colon Cancer Genetics Group, School of Clinical and Molecular Medicine, 2Clinical Genetics Department, and 3Public Health Sciences,
University of Edinburgh, and 4Medical Research Council (MRC), Human Genetics Unit, Edinburgh
DNA repair is a key process in the maintenance of genome integrity. Here, we present a large, systematically
collected population-based association study (2,239 cases; 1,845 controls) that explores the contribution to colo-
rectal cancer incidence of inherited defects in base-excision repair (BER) genes. We show that biallelic MUTYH
defects impart a 93-fold (95% CI 42–213) excess risk of colorectal cancer, which accounts for 0.8% of cases aged
!55 years and 0.54% of the entire cohort. Penetrance for homozygous carriers was almost complete by age 60
years. Significantly more biallelic carriers had coexisting adenomatous polyps. However, notably, 36% of biallelic
carriers had no polyps. Three patients with heterozygous MUTYH defects carried monoallelic mutations in other
BER genes (OGG1 and MTH1). Recessive inheritance accounted for the elevated risk for those aged !55 years.
However, there was also a 1.68-fold (95% CI 1.07–2.95) excess risk for heterozygous carriers aged 155 years,
with a population attributable risk in this age group of 0.93% (95% CI 0%–2.0%). These data provide the
strongest evidence to date for a causative role of BER defects in colorectal cancer etiology and show, to our
knowledge for the first time, that heterozygous MUTYH mutations predispose to colorectal cancer later in life.
These findings have clinical relevance for BER gene testing for patients with colorectal cancer and for genetic
counseling of their relatives.
Introduction
The role of base-excision repair (BER) in the mainte-
nance of genome stability is primarily to counter oxida-
tive DNA damage, which generates 8-oxoguanine prod-
ucts (8-oxoG). In humans, MYH (MIM 604933), OGG1
(MIM 601982), and MTH1 (MIM 600312) function in
consort to identify and repair 8-oxoG incorporated into
DNA, as well as to remove modified nucleoside. Re-
cent studies have identified biallelic germline defects
in MUTYH, in a proportion of families with multiple
colorectal polyposis, that are not due to germline APC
(MIM 175100 and 608456) mutations (Al-Tassan et al.
2002; Sieber et al. 2003). Although these studies provide
indirect evidence, it is important to establish whether
BER gene defects predispose to colorectal cancer (MIM
114500), to estimate the level of associated risk, and to
determine the attributable contribution of such defects
to overall disease incidence. Previous studies have pro-
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vided some supporting evidence that biallelic mutations
are associated with excess cancer risk (Croitoru et al.
2004; Fleischmann et al. 2004). Here, we present an
analysis of the largest cohort study to date, thereby af-
fording the opportunity to assess the effect of homo-
zygous and heterozygous BER gene mutations on colo-
rectal cancer risk. We assembled a large, systematically
recruited prospective cohort of patients from across
Scotland, shortly after diagnosis of colorectal cancer and
irrespective of family history. We also systematically re-
cruited healthy Scottish population control individuals
through the central National Health Service (NHS). Us-
ing this population-based resource, we set out to deter-
mine, by a genetic association strategy, the role of BER
genes in colorectal cancer susceptibility.
Subjects and Methods
Assembly of the Cohort and Sample Collection
A populationwide accrual of prospective colorectal
cancer cases has been in progress since 1999. Cases are
ascertained through direct contact with every surgical
and pathology department in Scotland. All cases had
histologically confirmed adenocarcinoma of the colon
or rectum. Blood DNA samples were obtained from pa-
tients after counseling and receipt of informed consent.
Population-based and age- and sex-matched controls were
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systematically identified, and blood DNA samples were
obtained from them. A questionnaire about family infor-
mation and lifestyle and medical history was completed
for patients and controls. Dietary risk-exposure data
were also collected by use of a validated food-frequency
questionnaire. For cases, tumor stage, pathology, clinical
presentation, as well as the presence of synchronous pol-
yps were documented. These studies are subject to all
necessary approvals from local ethics research committee
(LREC), multicenter research ethics committee (MREC),
and NHS research and development management in ev-
ery participating hospital.
Analysis of MUTYH Variants Y165C and G382D
A two-stage approach was used to efficiently identify
subjects carrying heterozygous or homozygous BER gene
variants. In the first step, assays were designed using
Primer Express v2.0 software (Applied Biosystems [AB])
for the two commonly reported variants, Y165C and
G382D, in patients with multiple polyposis. Allelic dis-
crimination for each variant employed allele-specific Taq-
Man MGB probes (AB), resolved on an ABI 7900 An-
alyzer, by use of SDS v2.1 software. Probe and primer
details are available on request. Each Y165C and G382D
variant identified by the TaqMan approach was con-
firmed by repeat DNA sequence analysis. In the second
phase, all subjects heterozygous for Y165C and G382D
underwent sequence analysis of the entire coding re-
gion of MUTYH, and the heterozygote cases were also
screened for OGG1 and MTH1 gene variants. GenBank
accession numbers for the genes are AF527839, NT_
022517, and NT_007819, respectively. PCR products
were treated with Exonuclease 1, shrimp alkaline phos-
phatase (Amersham Biosciences) and then were se-
quenced using ABI Big Dye terminator V3.0 chemistry,
with precipitated products separated on an ABI 3700.
Details of primer sequences are available on request.
Using this approach, we identified all homozygotes or
compound heterozygotes and any subjects in whom at
least one allele was either Y165C or G382D. However,
it should be noted that we could have missed some bial-
lelic carriers who did not have these two common vari-
ants. Hence, if anything, our estimates may underrep-
resent the contribution of BER genes, but we consider
this to be a marginal effect.
Assessment of Variants of BER Genes
Each variant identified by sequencing was confirmed
by repeat sequence analysis. Allele frequency for each
newly identified variant was then determined in at least
340 control chromosomes, to confirm that the variant
was not simply a common polymorphism. Any common
polymorphic variants were discarded, after which each
identified variant was subjected to rigorous bioinfor-
matic analysis. We used SIFT, which predicts deleterious
coding variants on the basis of cross-species conserva-
tion; PolyPhen, which predicts the effect by use of con-
servation and any protein structure available in the pub-
lic domain; T-Coffee, which aligns closely related En-
sembl orthologues; protein domains predicted using Pfam;
assessment of potential splicing effects by use of GEN-
SCAN; ESEfinder; and Berkeley Drosophila Genome
Project splice-site prediction.
Functional Analysis of MUTYH nt 9639 arg Variant
A variant was identified that was predicted to affect
splicing (MUTYH; nt 9639 arg). In this case, RNA was
extracted from blood leukocytes by use of Tri-reagent
(Sigma) and was processed to cDNA (Boeringer Mann-
heim First Strand Synthesis kit). A transcript product of
475 bp was amplified using exonic primers in exons 10
and 14 (primer details available on request). The product
was cloned using the Topo cloning kit (Invitrogen), and
positive colonies were amplified and sequenced. Similarly,
a genomic amplicon covering the nt 9639 arg change
and the G382D locus was cloned to demonstrate reces-
sive inheritance of the two variants.
Test for Association
Association was tested using Fisher’s exact test in a
table of genotype by colorectal cancer status,3# 2
thereby making no prejudgment on potential mode of
inheritance.
Estimate of Genotype Relative Risk
As an adaptation of the method of Hugot et al. (2001),
the genotype relative risk (GRR) is defined as follows:
Pr (DFAA)
GRR(AA)p p 1 ,
Pr (DFAA)
Pr (DFAa) Pr (AaFD)#Pr (AA)
GRR(Aa)p p ,
Pr (DFAA) Pr (AAFD)#Pr (Aa)
and
Pr (DFaa) Pr (aaFD)#Pr (AA)
GRR(aa)p p ,
Pr (DFAA) Pr (AAFD)#Pr (aa)
where is the frequency of genotype G amongPr (GFD)
cases and is the expected Hardy-Weinberg equi-Pr (G)
librium proportion, as obtained from the allele frequency
in the control population. The control population was
assumed to be a representative sample of the general
population. The 95% CIs for the GRRs were obtained
114 Am. J. Hum. Genet. 77:112–119, 2005
Table 1
Population GRR Associated with MYH Y165C
POPULATION AND GENOTYPE
NO. OF SUBJECTS
WITH GENOTYPE
GRR 95% CICase Control
Entire cohort ( ):Pp .228
GG 0 0 .00 .00–.00
AG 17 8 1.76 .90–4.16
AA 2,202 1,824 1.00 1.00–1.00
U55 ( ):Pp 1.000
GG 0 0 .00 .00–.00
AG 7 4 1.08 .37–3.72
AA 867 535 1.00 1.00–1.00
O55 ( ):Pp .180
GG 0 0 .00 .00–.00
AG 10 4 2.42 .96–8.71
AA 1,335 1,289 1.00 1.00–1.00
Table 2
Population GRR Associated with MYH G382D
POPULATION AND GENOTYPE
NO. OF SUBJECTS
WITH GENOTYPE
GRR 95% CICase Control
Entire cohort ( ):Pp .010
AA 8 0 121.23 44.48–325.10
GA 35 20 1.46 .93–2.43
GG 2,181 1,808 1.00 1.00–1.00
U55 ( ):Pp .402
AA 4 0 146.69 26.71–998.71
GA 12 6 1.24 .54–3.42
GG 864 531 1.00 1.00–1.00
O55 ( ):Pp .049
AA 4 0 102.19 22.09–333.10
GA 23 14 1.60 .93–2.95
GG 1,317 1,277 1.00 1.00–1.00
by bootstrapping 1,000 independent samples. For each
of the samples, the GRR was estimated, then the same
1,000 samples were ordered within each genotype, and
the 50th and 950th estimates were taken as the lower
and upper limits of the 95% CI.
Penetrance Estimates
Penetrance for colorectal cancer at a given age is de-
fined as the probability that a randomly selected indi-
vidual with genotype G will develop the disease by that
age, with the assumption that that individual does not
die of another cause. If Ax is the event “affected at age
, given being disease-free at x,” then the prob-x:x 1
ability that an individual is affected by age x, given the
genotype G, is . Similarly if is the event “not
—
Pr (A FG) Ax x
affected at age , given being disease-free at x,”x:x 1
then the probability that an individual is not affected by
age x, given genotype G, is . Population inci-
—
Pr (A FG)x
dence rates, , were obtained from Scottish HealthPr (A )x
Statistics, and the sex-average incidence rates were used.
Then
Pr (A FG) Pr (GFA )#Pr (A )x x xp ,— — —
Pr (A FG) Pr (GFA )#Pr (A )x x x
Pr (A FG) Pr (GFA )#Pr (A )x x xp ,—
1Pr (A FG) Pr (GFA )# [1Pr (A )]x x x
and
Pr(GFA )#Pr (A )x x
—
Pr (GFA )#[1Pr (A )]x xPr (A FG)p .x Pr (GFA )#Pr (A )x x1 —
Pr (GFA )#[1Pr (A )]x x
There were not enough observations for each age,
so was estimated using logistic regression (i.e.,Pr (GFA )x
age was used as a predictor of genotype). Similarly,
was estimated from controls. The penetrance
—
Pr (GFA )x
for genotype G is then defined as:
x
P p 1 [1Pr (A FG)] .G x
1
Estimate of CIs
The 95% CI for the estimate of the penetrance was
obtained by bootstrapping (i.e., by sampling with re-
placement) samples of cases and controls. A total of 500
independent samples were obtained of size equal to the
total number of cases and controls. Penetrance was es-
timated for each sample, and mean penetrance over rep-
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Table 3
Population GRR Associated with MUTYH Gene
POPULATION AND GENOTYPEa
NO. OF SUBJECTS
WITH GENOTYPE
GRR 95% CICase Control
Entire cohort ( ):Pp .001
MM 12 0 92.65 41.60–213.20
WM 45 28 1.35 .92–2.07
WW 2,160 1794 1.00 1.00–1.00
U55 ( ):Pp .976
MM 7 0 91.73 22.53–293.41
WM 14 10 .87 .43–1.72
WW 851 523 1.00 1.00–1.00
O55 ( ):Pp .014
MM 5 0 77.26 20.51–208.98
WM 31 18 1.68 1.07–2.95
WW 1,309 1,271 1.00 1.00–1.00
a W p wild-type allele; M p mutant allele.
licates and standard deviation (SD) were obtained. The
95% CI was calculated using the SD.mean 1.96
Results
Analysis of MUTYH Variants Y165C and G382D
All variants detected by TaqMan analysis were con-
firmed by genomic sequencing. Eight (0.36%) of the pa-
tients were homozygous for G382D. There were no ho-
mozygotes for Y165C, but three Y165C/G382D com-
pound heterozygotes were identified. There were no bial-
lelic defects in any control samples. Association was first
tested, using Fisher’s exact test in a table of ge-3# 2
notype by colorectal cancer status, thereby making no
prejudgment on potential mode of inheritance. Next,
GRR was calculated using the method of Hugot et al.
(2001), because the usual method, estimated by odds
ratio, is not possible because there were no homozygote
controls. The frequency of Y165C and G382D alleles
in cases and controls is presented in tables 1 and 2,
respectively.
The data presented in table 2 establish the fact that
the G382D locus is associated with colorectal cancer in
the complete cohort ( ; GRR 121; 95% CI 44–Pp .0104
325 for the G382D/G382D genotype). To explore any
age-specific effect, the cohort aged !55 years at diagnosis
(U55) was compared with those aged 155 years at diag-
nosis (O55) (table 2). Because of the lower number of
U55 subjects, there was no statistically significant asso-
ciation with G382D for the U55 cohort, whereas asso-
ciation for the O55 cohort remained statistically signifi-
cant ( ). There was no association with thePp .0494
Y165C locus (table 1), possibly because of the rarity of
the mutant variant in the Scottish population. We con-
sider the lack of association in the early-onset cohort to
be due primarily to the low allele frequency of these
individual variants and the resultant lack of statistical
power, even though this study involved large case and
control cohorts.
Significance of Other Variants in BER Genes
In light of prior genetic and functional evidence of an
additive effect of G382D and Y165C alleles (Al-Tassan
et al. 2002; Sieber et al. 2003), we next determined the
overall prevalence of biallelic defects, using a pragmatic
approach. To find second BER gene defects, DNA from
all carriers of monoallelic Y165C or G382D mutations
( ) was sequenced for each exon and intron/exonnp 74
boundary of MUTYH. BER genes OGG1 and MTH1
were also sequenced in cases with heterozygous Y165C
or G382D MYH alleles. All identified variants were ex-
cluded as polymorphisms by confirmation of wild-type
sequence in at least 340 control chromosomes and likely
functional relevance assessed by bioinformatic analysis,
as described in the “Subjects and Methods” section.
In addition to the eight G382D/G382D homozygotes
and the three Y165C/G382D compound heterozygotes
described above, we identified a further patient with a
heterozygous G382D mutation who had a second ge-
nomic MUTYH defect (nt 9639 arg) that we consider
to be pathogenic. This variant was confirmed to reside
on the wild-type allele by genomic DNA cloning and
sequencing. The variant was predicted to affect splicing.
This was confirmed by cDNA analysis, which showed
only mutant G382D transcript and no wild-type tran-
script. Thus, the patient was hemizygous for G382D at
the RNA level. The TaqMan approach used for the
G382D variant identified all nt 9639 arg variants, so
we have systematically screened all samples for this vari-
ant. Thus, the genotyping strategy would have identified
the MUTYH defect nt 9639 arg variant with equal sen-
sitivity in cases and controls. Hence, we have included
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this variant in further analyses of the effect of overall
MUTYH genotype, for a total of 12 biallelic carriers (all
cancer patients) and 73 subjects (45 patients and 28
controls) with monoallelic MUTYH alleles that we are
confident are pathogenic (table 3).
We next considered other samples that might have a
second BER gene defect. In all, there were an additional
three samples with heterozygous G382D or Y165C al-
leles that had another BER gene defect that we consider
likely to be pathogenic, but we cannot confirm or refute
this. Hence, we did not include these other BER alleles
in the analysis of the overall effect of putative BER gene
defects (table 3). Two patients with Y165C or G382D
mutations (one of each) had a second allelic variant in
MTH1 (R31Q) that has been reported elsewhere in mul-
tiple polyposis (Sieber et al. 2003). Codon 31 of MTH1
is evolutionarily conserved, and bioinformatics interro-
gation suggests that the R31Q mutation affects protein
function. Furthermore, we identified the variant in a to-
tal of 2 of 84 patient chromosomes, compared with 0
of 368 control chromosomes, which suggests that this
is not a common polymorphic variant in the population
(although we cannot directly compare R31Q prevalence,
because these are two different groups). Taken together
with previously published studies, we consider that the
MTH1 R31Q variant is likely to be functionally im-
portant and consequently is likely to be a pathogenic
mutation. One patient with an MTH1 R31Q variant
also had a P391L variant in MYH that is at a highly
conserved residue and is predicted to affect protein func-
tion. However, the significance of this variant is unclear,
in light of the above discussion. A third patient with a
monoallelic MYH G382D allele also had a variant in
OGG1 (R197W). The variant is at a highly conserved
codon, and bioinformatics analysis predicts a profound
effect on protein function; again, the significance of this
cannot currently be determined.
Analysis of the MUTYH Gene and Colorectal Cancer
Risk
To assess biallelic inactivation of the entire gene, we
calculated the combined risk for all significant MUTYH
variants that had been analyzed in the complete cohort.
This analysis included eight G382D/G382D homozy-
gotes, three Y165C/G382D compound heterozygotes,
and one nt 9639 arg /G382D compound heterozygote,
as discussed above. The data presented in table 3 con-
vincingly establish the fact that the MUTYH gene is sig-
nificantly associated with colorectal cancer ( ).Pp .0012
Biallelic inactivation imparts an overall 93-fold excess
risk (GRR 93; 95% CI 42–213). As was the case for
analysis of the G382D variant alone, the reduction in
numbers for the U55 cohort resulted in loss of statistical
power to detect association with the gene in that group,
although the O55 group remains significant (Pp
)..0138
Separation of the cohorts by age reveals an age-specific
risk effect and shows, for the first time, a significant mono-
allelic effect for late-onset disease when the empirical
CIs produced by bootstrap analysis are used. There was
a 1.68-fold excess risk (95% CI 1.07%–2.95) for het-
erozygous carriers aged 155 years and a population-
attributable risk in this age group of 0.93% (95% CI
0%–2.0%). However, these results should be taken with
some caution, because the significance was marginal,
despite the fact that we have studied large case/control
cohorts. Furthermore, analysis by use of standard CIs
for the odd ratios in testing for association gave an al-
most significant result ( ; 95% CI 0.93–3) forPp .085
a monoallelic effect. It was only with bootstrap analysis
that this effect was significant at the 5% level. None-
theless, these are novel observations that suggest that het-
erozygous MUTYH variants impart a modest increased
risk later in life.
Estimate of Penetrance for MUTYH Gene Defects
We first estimated penetrance for G382D alleles at the
MUTYH locus using the method of Satagopan et al.
(2001), modified for application to a recessive trait. Fig-
ure 1 shows age-specific penetrance and 95% CIs for the
G382D/G382D genotype alone. Of G382D/G382D car-
riers, ∼55% developed colorectal cancer by age 40 years,
and cancer had developed in all G382D/G382D carriers
by age 65 years. Next, we estimated age-specific pene-
trance for all systematically determined biallelic defects
identified in MUTYH (fig. 2). This analysis suggests that
biallelic inactivation of the gene is highly penetrant, with
all homozygous carriers developing cancer by age 60
years.
These findings establish the fact that there is a sub-
stantially elevated colorectal cancer risk early in life for
people with biallelic MYH defects.
Synchronous Polyps in Biallelic MUTYH Cancer
Patients
Data on polyp prevalence in cancer patients by geno-
type are presented in table 4. It is noteworthy that 4
(36%) of the 11 biallelic carriers with cancer for whom
we had reliable polyp information had no concurrent
metaplastic or adenomatous polyps. This emphasizes the
fact that using polyp presence as a surrogate to enrich
for MUTYH mutation carriers is quite insensitive. The
data presented in table 4 show that there was a clear
relationship between synchronous polyps and MUTYH
genotype (all polyp types ; adenomatous pol-Pp .025
yps ; multiple adenomas [with usePp .007 P ! .0001
of Fisher’s Exact Test]). In all, 64% of biallelic carriers
had polyps; in all cases, these were multiple adenomas.
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Figure 1 Penetrance curve of the MYH G382D locus. Age-related penetrance was estimated and plotted for all three genotypes, including
95% CIs.
The same analyses were performed, but with comparison
of only the heterozygotes and wild-type genotypes, using
contingency tables; there were no significant re-2# 2
sults for presence of polyps with a heterozygote genotype
( ).P 1 .24
Discussion
Taken together, these data establish conclusively that de-
fects in BER genes predispose to colorectal cancer. The
findings provide robust evidence of causal involvement
of biallelic BER gene defects in early-onset colorectal
cancer, given the fact that there was complete penetrance
by age 60 years. These findings substantially extend pre-
vious indirect evidence of involvement in colorectal can-
cer susceptibility through study of families with multiple
polyposis (Al-Tassan et al. 2002; Sieber et al. 2003) and,
combined with our findings of an excess of adenomatous
polyps, suggest that polyps in such cases are premalig-
nant. Our findings are also supported by previous sug-
gestive evidence from smaller studies that lacked power
to definitively establish whether there is an association
between biallelic MUTYH variants and colorectal cancer
(Enholm et al. 2003; Fleischmann et al. 2004; Wang et
al. 2004).
There is only one previous study (Croitoru et al.
2004) that has shown an association between biallelic
MUTYH variants and colorectal cancer. In that study,
the authors proposed indirect evidence of a heterozy-
gous effect because they observed nonrandom loss of
heterozygosity of the wild-type allele in colorectal can-
cer. The findings presented here do, in fact, support their
view and provide the first evidence of a modest colo-
rectal cancer risk associated with heterozygous MUTYH
mutations later in life. It is noteworthy that we found
evidence of a significant excess risk associated with het-
erozygous MUTYH gene defects only when we consid-
ered the entire gene effect, and, importantly, this effect
emerged only for late-onset disease. The effect was small
and only just significant, and the results should be taken
with some caution. Bootstrapping CIs are generally more
robust than asymptotic CIs; however, it must be noted
that asymptotic CIs for the odds ratio gave a slightly
less significant result for the same data set. It is also
possible that some of the excess risk we are detecting
in heterozygotes is due to variants on the other allele
that we have not detected. Data from mouse models
indicates that, on an ApcMin/ background, monoallelic
Myh inactivation does not increase tumor burden or the
signature G-T transversions of the remaining Apc allele
in the mouse tumors (Sieber et al. 2004). However, the
study presented here is the largest to date, and previous
studies have concentrated on early-onset disease or
mixed cohorts (Fleischmann et al. 2004; Wang et al.
2004). Thus, only studies involving even larger numbers
of later-onset cancer cases might be able to confirm our
evidence of a monoallelic effect.
The study presented here emphasizes the requirement
for very large population-based cohorts for robust as-
sessment of the role of putative colorectal cancer sus-
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Figure 2 Penetrance curve of the MUTYH gene. All systematically verified and functionally deficient variants were included in the
calculations, to estimate the penetrance of the entire gene. This therefore includes variants G382D, Y165C, and nt 9639 arg. W p wild-type
allele; M p mutant allele.
Table 4
MUTYH Genotype and the Presence of Synchronous Benign Polyps
GENOTYPE
NO. (%) OF SUBJECTS WITH
No Polyps All Polyp Types Multiple Polyps Adenomas Multiple Adenomas
MM ( )np 11 4 (36) 7 (64) 7 (64) 7 (64) 7 (64)
WM ( )np 44 31 (70) 13 (30) 5 (11) 8 (18) 3 (7)
WW ( )np 1,167 859 (74) 308 (26) 100 (9) 224 (19) 54 (5)
NOTE.—Adenomas were either tubular or tubulovillous subtypes. Other polyps were metaplastic/hyper-
plastic. Three or more polyps were categorized as “multiple.” Reliable concurrent polyp-prevalence data
were not available for all patients with cancer, so the numbers for whom information was available are
provided for each genotype.
ceptibility alleles by genetic association strategies, even
when relative risk is high. The relatively low allele fre-
quency is likely to be a feature of many other cancer
susceptibility alleles and raises some concerns for future
power to detect associations where there is no prior
biological hypothesis behind locus selection.
For clinical purposes, it is interesting to note that
more than one-third of biallelic carriers did not have any
synchronous polyps. This emphasizes the fact that use
of polyps as an approach to enrich for MUTYH carriers
with cancer is quite insensitive, in contrast with the find-
ings of APC-negative multiple polyposis cases (Sampson
et al. 2003; Sieber et al. 2003). Overall, there was an
excess of synchronous polyps in biallelic carriers com-
pared with others in this cohort, especially when ade-
nomatous lesions were considered. Interestingly, mono-
allelic carriers did not appear to have an excess of
polyps, suggesting the possibility that the excess cancer
risk for heterozygotes later in life might be through a
different mechanism.
Data presented here indicate that 1 of 50 patients who
are diagnosed with colorectal cancer at age !40 years
and 1 of 150 patients aged !55 years carry biallelic
mutations in BER genes that are causally linked to can-
cer development. In defining the mutation carrier fre-
quency for MUTYH and other BER genes, the present
work informs future decisions about offering genetic
testing to patients with early-onset colorectal cancer.
Furthermore, the findings also have substantial clinical
importance for the siblings of carriers, who have at least
a 1/4 risk of colorectal cancer by age !60 years, by
nature of the recessive genetic trait segregating in the
family. Very large studies of late-onset disease-carrier
status are required to replicate or refute the evidence
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presented here that monoallelic MUTYH defects con-
tribute to colorectal cancer incidence.
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Web Resources
Accession numbers and URLs for data presented herein are
as follows:
Berkeley Drosophila Genome Project, http://www.fruitfly.org/
seq_tools/splice.html
ESEfinder, http://rulai.cshl.edu/tools/ESE/
GenBank, http://www.ncbi.nlm.nih.gov/GenBank/ (for MUTYH
[accession number AF527839], OGG1 [accession number
NT_022517], and MTH1 [accession number NT_007819])
GENSCAN, http://genes.mit.edu/GENSCAN.html
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for MYH, OGG1, MTH1, APC,
and colorectal cancer)
Pfam, http://www.sanger.ac.uk/Software/Pfam/
PolyPhen, http://www.bork.embl-heidelberg.de/PolyPhen/
SIFT, http://blocks.fhcrc.org/%7Epauline/SIFT
T-Coffee, http://www.ch.embnet.org/software/TCoffee.html
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